Chimerix Inc

Chimerix — Corporate Update (November 2021)

32 slides from Chimerix's corporate update, Nov 22, 2021

  1. Slide 1: Post Society for Neuro-Oncology Management Conference Call

    Post Society for Neuro - Oncology Management Conference Call November 22, 2021 © 2021 Chimerix, Inc

  2. Slide 2: Forward-Looking Statements

    2 Forward - Looking Statements These slides contains forward - looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to risks and uncertainties that could cause actual results to differ materially from those projected. Forward - looking statem

  3. Slide 3: Clinical Efficacy of ONC201 in Recurrent H3 K27M-Mutant Diffuse Midline Glioma Patients

    Clinical Efficacy of ONC201 in Recurrent H3 K27M- Mutant Diffuse Midline Glioma Patients Review: Society for Neuro-Oncology 2021 Presentation Isabel Arrillaga-Romany, MD, PhD Massachusetts General Hospital Boston, MA

  4. Slide 4: Diffuse Midline Glioma, H3 K27M-mutant

    4 Diffuse Midline Glioma, H3 K27M - mutant • H3 K27M is detected in 50 - 90% of midline gliomas • More prevalent in pediatric populations but also prevalent adults as well • Highly aggressive malignancy; invariably lethal • No effective drug therapies to date for recurrence • No definite objective r

  5. Slide 5: ONC201 Is a DRD2 Antagonist/ClpP Agonist

    5 ONC201 Is a DRD2 Antagonist/ClpP Agonist • Oral small molecule • Once weekly dosing based on pharmacodynamics • Well tolerated • DRD2 antagonist and ClpP agonist that induces tumor cell apoptosis Allen et al., Science Translational Medicin e , 2013 Ishizawa et al, Science Signaling , 2016 Kline et

  6. Slide 6: Integrated Efficacy Analysis: Objective and Eligibility Criteria

    6 Integrated Efficacy Analysis: Objective and Eligibility Criteria Objective • To evaluate monotherapy efficacy of ONC201 in recurrent H3 K27M - mutant diffuse midline glioma Eligibility • Age ≥2yo and received ONC201 under studies ONC006, ONC013, ONC014, ONC016, or ONC018 • Diffuse glioma with a kn

  7. Slide 7: Endpoints

    7 Endpoints Primary Endpoint • Overall response rate by RANO - HGG criteria Secondary Endpoints • Overall response rate by RANO - Low Grade Glioma (LGG) criteria • Duration of response 1 • Time to response 1 • Best overall response 1 • Disease Control Rate 1 • Progression - free survival 1 • Overall

  8. Slide 8: Response Assessment Criteria for Glioma (RANO-HGG)

    8 • DMG with H 3 K 27 M typically have both enhancing and non - enhancing disease components • RANO - HGG responses defined by decrease in enhancing disease • RANO LGG response defined by decrease in T 2 FLAIR Response Assessment Criteria for Glioma RANO - HGG T2 - FLAIR T 1 - G d+

  9. Slide 9: Response Assessment Criteria for Glioma (RANO-LGG)

    9 Response Assessment Criteria for Glioma RANO - LGG T2 - FLAIR T 1 - G d+ • RANO LGG response defined by decrease in T2 FLAIR

  10. Slide 10: Patient Demographics and Disease Characteristics

    10 Patient Demographics and Disease Characteristics 1 Multifocal disease includes non - target lesions 2 Sum of product of diameters of enhancing target lesions per BICR

  11. Slide 11: Dosing & Disposition

    11 Dosing & Disposition • Dosing - Oral 625 mg ONC201 (scaled by body weight for pediatric patients) - Once every week with exception of one patient dosed once every 3 weeks • Last patient enrolled February 26, 2020 • Data cutoff for analysis May 31, 2021 • Median follow - up 18.8 months • Dispositi

  12. Slide 12: Serious Adverse Events

    12 Serious Adverse Events 1 Specific preferred terms occurring in more than one patient are listed; 25 patients had at least one SAE 2 Possibly related per investigator assessment; unlikely related per sponsor assessment

  13. Slide 13: Overall Response Rate (RANO-HGG)

    13 Overall Response Rate (RANO - HGG) 1 Integrated RANO HGG criteria assessment by dual reader BICR 2 Five overall radiographic SD accompanied by increase in corticosteroids; 3 overall radiographic PD accompanied by decrease in corticosteroids 3 Three patients did not have on - treatment monotherapy

  14. Slide 14: Waterfall Plot (RANO-HGG)

    14 Waterfall Plot (RANO - HGG) * Change > 100%, CR=complete response, PR=partial response, SD=stable disease, NE=not evaluable, PD=progressive disease SPD=sum of products of perpendicular diameters (target enhancing lesions per BICR) Only patients with measurable target enhancing lesions by BICR at

  15. Slide 15: Spider Plot (RANO-HGG)

    15 Spider Plot (RANO - HGG) SPD=sum of products of perpendicular diameters (target enhancing lesions per BICR) Only patients with measurable target enhancing lesions by BICR at baseline and with post - baseline evaluations are included. Three patients did not have on - treatment monotherapy MRIs ava

  16. Slide 16: Overall Response Rate (RANO-LGG)

    16 Overall Response Rate (RANO - LGG) 30.0% (95% CI: 17.9 - 44.6%) achieved an objective response by RANO - HGG and/or RANO - LGG criteria 1 Integrated RANO LGG criteria assessment by dual reader BICR 2 Eight overall radiographic SD accompanied by increase in corticosteroids; 3 overall radiographic

  17. Slide 17: Waterfall Plot (RANO-LGG)

    17 Waterfall Plot (RANO - LGG) * Change > 100%, PR=partial response, MR=minor response, SD=stable disease, NE=not evaluable, PD=progressive disease SPD=sum of products of perpendicular diameters (target non - enhancing lesions per BICR) Only patients with measurable target lesions by BICR at baselin

  18. Slide 18: Case Study

    18 Case Study • Integrated Diagnosis: DMG, H3K27m mutation • Molecular Features: MGMT promoter unmethylated, IDH wildtype. • Significant response to treatment both by RANO - HGG and RANO - LGG by cycles 8 and 10; response was sustained for over one year

  19. Slide 19: Progression-Free Survival

    19 Progression - Free Survival PFS (95% CI) 6 Months 35% (21 – 49) 12 Months 30% (17 – 44)

  20. Slide 20: Overall Survival

    20 Overall Survival OS = overall survival OS (95% CI) 12 Months 57% (41 – 70) 24 Months 35% (21 – 49)

  21. Slide 21: Performance Status and Corticosteroid Use

    21 Performance Status and Corticosteroid Use Corticosteroids 3 1 Corticosteroid response: ≥50% reduction in average daily corticosteroid dose compared to baseline with stable or improved KPS/LPS. Must be confirmed at next analysis timepoint. Corticosteroids were converted into a dexamethasone equiva

  22. Slide 22: Summary

    22 Summary • Integrated response analysis results - RANO - HGG criteria assessed by dual reader BICR • ORR 20% (95% CI: 10 – 34%) • Median DOR 11.2 months (95% CI: 3.8 – not reached) • Median time to response 8.3 months (range 1.9 – 15.9) • Disease control rate 40% (95% CI: 26 – 55%) • PFS at 6 mont

  23. Slide 23: Acknowledgments

    23 Acknowledgments • Children’s National Medical Center - Lindsay Kilburn • Columbia University - Andrew Lassman • Levine Cancer Inst (LCI) - Ashley Sumrall • Miami Cancer Institute - Yazmin Odia • MD Anderson Cancer Center - Rebecca Harrison - Nazanin Majd • Dana Farber Cancer Inst - Patrick Wen -

  24. Slide 24: Supplemental Material and Management Discussion

    Supplemental Material and Management Discussion © 2021 Chimerix, Inc

  25. Slide 25: Recurrent Glioma Remains a High Unmet Need

    25 • H3 K27M - mutant DMG is a grade IV by WHO • FDA has acknowledged available therapy is palliative - Often not possible to resect - Recurrence inevitable after first - line radiation - Chemotherapy ineffective; objective responses by RANO - HGG have not been reported • Survival in grade II - IV r

  26. Slide 26: Waterfall Plot (RANO-HGG) Stratified by Performance Status

    26 Waterfall Plot (RANO - HGG) Stratified by Performance Status • Expectedly, patients with higher PS were more likely to respond to treatment - 100: 1/2 (50%) - 90: 4/14 (29%) - 80: 4/20 (20%) - 70: 1/7 (14%) - 60: 0/7 (0%) • Consistent with hypothesis that treating earlier in disease course may en

  27. Slide 27: Waterfall Plot (RANO-HGG) Stratified by Age

    27 Waterfall Plot (RANO - HGG) Stratified by Age • Responses observed across age groups: - <18 years: 1/4 (25%) - 18 - 40 years: 5/32 (16%) - > 40 years: 4/14 (29%) • RANO - HGG response of 8 - year - old subject confirms activity in this population © 2021 Chimerix, Inc

  28. Slide 28: Pediatric Case Study

    28 Pediatric Case Study • 8 - year - old thalamic H3.3 K27M DMG initially diagnosed in May 2018 • First - line therapy: radiation, dasatinib, everolimus and bevacizumab • Second - line therapy: 375mg weekly ONC201 monotherapy initiated Apr 2019 following progression on first - line therapy - Clinica

  29. Slide 29: Adult Case Study

    29 Adult Case Study • 54 - year - old thalamic H3 K27M DMG diagnosed in Nov 2018 • First - line therapy: radiation and temozolomide • Second - line therapy: 625mg weekly ONC201 monotherapy initiated May 2019 - Corticosteroid elimination and radiographic regression over >1.5 years of therapy 12.9 mon

  30. Slide 30: ONC201 Activity in Non-Midline H3 K27M Diffuse Glioma

    30 • Two of five patients had objective responses by RANO - HGG per investigator but not BICR 1 - Both patients had a response by RANO - LGG per BICR o Patients were on - treatment for 14 and 23 months - Responses were associated with increased mobility and alertness • Suggest activity may not be re

  31. Slide 31: RANO Responses Correspond with Survival & Clinical Benefit

    31 All patients RANO HGG Responders RANO HGG and/or LGG R es pond ers All Other Patients N 50 10 15 35 PFS at 12 months 30% 1 90% 67% 0% (number of patients censored) (0) (2) (8) OS at 24 months 35% 1 80% 53% 0% (number of patients censored) 2 (2) (5) (8) Corticosteroids response 3 47% 100% 100% 20%

  32. Slide 32: Summary

    32 • ONC201 monotherapy exhibited durable and clinically meaningful efficacy in recurrent H3 K27M - mutant DMG patients - RANO - HGG criteria assessed by dual reader BICR • ORR 20% (95% CI: 10 – 34%) • Median DOR 11.2 months (95% CI: 3.8 – not reached) • Median time to response 8.3 months (range 1.9

Chimerix — Corporate Update (November 2021) on 6ix